Medtech in a Minute: InnoSIGN Splits from Philips, MDUFA V, and More
Quickly catch up on the latest medtech news from FDA, Philips, and others.
March 28, 2022
FDA Releases MDUFA V Details
Details surrounding the proposed fifth iteration of the medical device user fee amendments (MUDFA V) have been made public. Under the proposed measure, FDA would be authorized to collect at least $1.78 billion in user fees over five years, plus additional funding, for a total of up to $1.9 billion to further improve performance if specified goals are met. FDA said this funding would provide critical resources to its medical device review program. The agency said it will hold a virtual public meeting April 19 to obtain comments on the medical device user fee amendments.
InnoSIGN Separates from Philips
InnoSIGN has completed its spinout from Philips with the help of an $8 million financing. The new company was formed around the OncoSIGNal pathway activity profiling technology. The OncoSIGNal technology is mRNA-based tests that measure the activity of signal transduction pathways in cancer and immune cells to predict how patients will respond to targeted drugs.
And in case you missed our last Medtech in a Minute report...
GE Launches Digital Health Platform
GE Healthcare has introduced the Edison Digital Health platform, a vendor-agnostic hosting and data aggregation platform with an integrated artificial intelligence (AI) engine. The platform is being developed to enable hospitals and healthcare systems to effectively deploy clinical, workflow, analytics, and AI tools aimed at the improvement of care delivery, the promotion of high-efficiency operations, and the increase of revenue growth, while also supporting reduction in the IT burden that typically comes with installing and integrating apps across the enterprise.
Verily's Prostate Cancer Collab
Verily is working with Lumea, a digital pathology specialist, to improve prostate cancer pathology. The agreement brings together Verily’s artificial intelligence algorithms and Lumea’s end-to-end digital pathology platform with the objective to develop products that can diagnose, prognose, and guide prostate cancer therapy selection with improved objectivity and efficiency.
Dexcom for the CGM Win
One of medtech’s most anticipated devices has won approval in Europe. Dexcom received a CE mark for its G7 continuous glucose monitoring (CGM) system for people with diabetes over the age of two, including pregnant women. The company also plans to roll out an updated CGM algorithm this year.
About the Author
You May Also Like